INTRODUCTION: Little is known regarding the success, failure, or complication rates of advanced implant procedures in patients after discontinuation therapy of long-term medications for the treatment of chronic myelogenous leukemia (CML). This case report presents initial results of a case involving implant placement in the mandible and maxilla as well as reduction of palatal oral pigmentation in a patient discontinuing long-term tyrosine kinase inhibitor (TKI) therapy for CML. CASE PRESENTATION: A 57-year-old male was referred to the Department of Periodontics, University of Washington, Seattle, Washington, for an assessment of edentulous areas (tooth sites #3 and #14) and failing tooth #19. Previous medical treatment included oral administration (>10 years) of TKI for the treatment of CML. Systemic complications arising from long-term TKI therapy were treated with discontinuation of this medication. Concurrently, after multispecialty dental and medical consultation, extraction of tooth #19 with immediate implant placement and bilateral sinus augmentation with simultaneous implant placement were successfully performed during three separate surgical appointments. Additionally, marked reduction of oral palatal pigmentation was observed during the surgical and restorative phases after TKI discontinuation. CONCLUSIONS: Patients with a history of long-term TKIs for CML are at risk for developing complications that result in discontinuation of therapy. Long-term benefits of therapy may allow these patients to enjoy remission with an extended and improved quality of life. Patients undergoing discontinuation therapy may seek dental care. Therefore, dental providers need to understand these systemic interactions and, with multispecialty consultation, may help effectively treat these individuals.
INTRODUCTION: Little is known regarding the success, failure, or complication rates of advanced implant procedures in patients after discontinuation therapy of long-term medications for the treatment of chronic myelogenous leukemia (CML). This case report presents initial results of a case involving implant placement in the mandible and maxilla as well as reduction of palatal oral pigmentation in a patient discontinuing long-term tyrosine kinase inhibitor (TKI) therapy for CML. CASE PRESENTATION: A 57-year-old male was referred to the Department of Periodontics, University of Washington, Seattle, Washington, for an assessment of edentulous areas (tooth sites #3 and #14) and failing tooth #19. Previous medical treatment included oral administration (>10 years) of TKI for the treatment of CML. Systemic complications arising from long-term TKI therapy were treated with discontinuation of this medication. Concurrently, after multispecialty dental and medical consultation, extraction of tooth #19 with immediate implant placement and bilateral sinus augmentation with simultaneous implant placement were successfully performed during three separate surgical appointments. Additionally, marked reduction of oral palatal pigmentation was observed during the surgical and restorative phases after TKI discontinuation. CONCLUSIONS: Patients with a history of long-term TKIs for CML are at risk for developing complications that result in discontinuation of therapy. Long-term benefits of therapy may allow these patients to enjoy remission with an extended and improved quality of life. Patients undergoing discontinuation therapy may seek dental care. Therefore, dental providers need to understand these systemic interactions and, with multispecialty consultation, may help effectively treat these individuals.
Authors: Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim Journal: J Natl Cancer Inst Date: 2011-03-21 Impact factor: 13.506
Authors: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes Journal: Blood Date: 2013-05-23 Impact factor: 22.113
Authors: Y Wang; Y Zhao; L Liu; L Zhang; H Xiao; K Wu; Y Xu; Y Hu; H Fu; W Cao; Y Luo; H Huang Journal: Clin Exp Dermatol Date: 2014-01-31 Impact factor: 3.470